Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + pm-Pac + Platinum in Advanced Squamous NSCLC
NCT07009925Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ivonescimab in squamous cell carcinoma of the lung (LSCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT07009925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009925.